Phase 1B Study of buparlisib with Bortezomib in Defined Genetic Subgroups of Patients with Relapsed or Refractory Multiple Myeloma
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 10 May 2018
At a glance
- Drugs Buparlisib (Primary) ; Bortezomib
- Indications Multiple myeloma
- Focus Adverse reactions
- Acronyms Bubble
- 03 May 2018 Status changed from recruiting to active, no longer recruiting.
- 04 Apr 2016 Status changed from not yet recruiting to recruiting, as reported by ISRCTN: Current Controlled Trials.
- 08 Mar 2016 Planned initiation date changed from 1 Jun 2015 to 1 Apr 2016 as per ISRCTN: Current Controlled Trials record.